Torrent Pharmaceuticals
Torrent Pharmaceuticals Limited, commonly known as Torrent Pharma, is a prominent player in the global pharmaceutical industry, headquartered in Ahmedabad, India. Founded in 1959, the company has established a strong presence in various operational regions, including North America, Europe, and emerging markets across Asia and Africa. Specialising in the development, manufacturing, and marketing of a diverse range of generic and branded pharmaceuticals, Torrent Pharma focuses on therapeutic areas such as cardiovascular, central nervous system, and anti-infectives. The company is recognised for its commitment to quality and innovation, which has led to significant milestones, including a robust portfolio of over 200 products. With a strong market position, Torrent Pharmaceuticals has garnered accolades for its research and development capabilities, making it a trusted name in the industry. Its dedication to improving patient outcomes through affordable healthcare solutions sets it apart in a competitive landscape.
DitchCarbon Score
How does Torrent Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Torrent Pharmaceuticals's score of 39 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Torrent Pharmaceuticals's reported carbon emissions
In 2024, Torrent Pharmaceuticals reported total carbon emissions of approximately 915,620 kg CO2e, comprising about 15,294,000 kg CO2e from Scope 1 and about 76,268,000 kg CO2e from Scope 2. This reflects a significant reduction in emissions compared to previous years, with total emissions decreasing from about 126,926,000 kg CO2e in 2022 and 124,099,000 kg CO2e in 2021. The company has demonstrated a commitment to reducing its carbon footprint, achieving a notable decrease in emissions intensity per rupee of turnover, with a figure of approximately 0.024551 kg CO2e in 2024, down from 0.036326 kg CO2e in 2023. However, there are currently no disclosed reduction targets or climate pledges under the Science Based Targets initiative (SBTi) or other frameworks. Torrent Pharmaceuticals continues to focus on its emissions from Scope 1 and Scope 2, while no data is available for Scope 3 emissions. The company’s ongoing efforts to enhance sustainability and reduce its environmental impact are evident in its annual reporting and emissions management strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 28,072,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 96,026,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Torrent Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
